BlackRock Health Sciences Term Trust

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Silexion Therapeutics

Micware

GCL Global

MetaVia

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

Ordinary dividend (cash)

Ex Date: 2026.06.15 (EST), Cash dividend 0.11 USD

BMEZ

Investors are presented with a 10.3% average dividend opportunity from two closed-end funds (CEFs) amid rising inflation. The strategy involves securing high yields now while anticipating falling interest rates in the future. The DoubleLine Income Solutions Fund (DSL) offers a 12% payout, while the BlackRock Health Sciences Term Trust (BMEZ) provides a 9.3% yield. Both funds are currently trading at significant discounts to NAV, making them attractive investments as AI advancements and economic conditions evolve.

Forbes

Doubleline Income Solutions

Goldman Sachs

Merck

Moderna

Gilead Sciences

GS Hldg R

2 High Yield CEFs To Beat Inflation Now, Deflation Later

TELO

ARKG

Telomir reported peer-reviewed preclinical data indicating that Telomir-Zn improves survival and reduces hepatic copper in a Wilson’s disease model. Key findings include reduced copper-driven ROS amplification, lower liver injury biomarkers, and improved locomotor performance in zebrafish. The company plans to continue its Wilson’s disease program and advance its Telomir-1 TNBC program toward Phase 1/2 clinical initiation.

TradingView

Telomir Pharmaceuticals

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares US Pharma

VG Health

Health Care Select Sector SPDR

iShares Biotechnology ETF

VanEck Biotech ETF

Telomir Reports Peer-Reviewed Preclinical Telomir-Zn Data Showing Dose-Dependent Survival & Reduced Hepatic Copper

Last week's inflation reports present a 10.3% dividend opportunity through two closed-end funds (CEFs). The strategy involves securing this yield now before anticipated interest rate declines. The DoubleLine Income Solutions Fund (DSL) offers a 12% payout, while the BlackRock Health Sciences Term Trust (BMEZ) provides a 9.3% yield. Both funds are currently undervalued, making this an opportune time for investment as AI impacts inflation and wage growth.

nasdaq

The Interest Rate "Surprise" Everyone's Ignoring (and the 10.3% Dividend That Profits From it)

BlackRock announced updates to the managed dividend plans for BMEZ, BSTZ, and BTX

Zhitong

BlackRock Health Sciences Term Trust (BMEZ) announced the final results of its tender offer for up to 40% of its outstanding common shares, which expired on April 17, 2025. The offer was undersubscribed, and the Fund will purchase all properly tendered shares. Payment for accepted shares is expected by April 25, 2025. The purchase price is set at $14.2086, equating to 99.5% of the Fund’s net asset value per share as of April 21, 2025.

StockTitan

Essential Properties Realty

BlackRock

BlackRock Health Sciences Term Trust (BMEZ) Announces Final Results of Tender Offer | BMEZ Stock News

BlackRock Health Sciences Term Trust (BMEZ) announced the expiration and preliminary results of its tender offer for up to 40% of its outstanding common shares. The tender offer, which began on March 21, 2025, was undersubscribed, with 38,753,713 shares tendered. Shareholders who properly tendered their shares will receive 99.5% of the Fund's net asset value as of April 21, 2025. Final results are expected to be announced around the same date.

BlackRock Health Sciences Term Trust (BMEZ) Announces Expiration and Preliminary Results of Tender Offer | BMEZ Stock News